Identification of New Candidate Genes for Hereditary Predisposition to Uveal Melanoma
Recruiting · NCT06550674 · Interventional (participants receive a specific treatment) · Lead sponsor: Centre Jean Perrin
View the official record on ClinicalTrials.gov →Interventions studied
Constitutional exome analysis
What this trial is about
Only 20% of familial uveal melanomas are explained by a hereditary predisposition, implying the presence of as yet unknown hereditary predispositions. This hypothesis is reinforced by epidemiological studies revealing an excess risk of prostate cancer, thyroid cancer and leukemia in patients who have developed uveal melanoma, even though these cancers are not part of the tumor spectrum of known hereditary predispositions to uveal melanoma (BAP1, MBD4). The identification of new candidate genes, once validated, would enable us to offer these families appropriate surveillance.
Who can take part
Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not applicable (e.g. observational or device study)
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Patient with a personal history of uveal melanoma (newly diagnosed, under treatment or in follow-up)
- Enrolled in or benefiting from a social security scheme
Exclusion criteria
- Causal pathogenic variation identified in BAP1 or MBD4
- Patient does not consent to constitutional genetic analysis for diagnostic purposes
- Patient not consenting to a constitutional genetic analysis for research purposes
- Pregnant and breast-feeding women
- Patients under guardianship or trusteeship
Where it is running
1 location listed.
- Centre Jean PERRIN - Clermont-Ferrand, Puy-de-Dôme, France